Anlon Healthcare Ltd (AHCL) is currently trading at 25.56 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Anlon Healthcare is an Indian pharmaceutical manufacturer of pharma intermediates and active pharmaceutical ingredients (APIs) that is actively transitioning into an integrated pharmaceutical platform encompassing intermediates, APIs, custom manufacturing (CDMO), finished dosage formulations, industrial and fine chemicals, peptides, biologics and medical devices through organic expansion and recent acquisitions. Q1 FY27 was transformational: consolidated revenue rose to ₹87.62 crore from ₹33.31 crore in Q1 FY26 primarily due to consolidation of recent acquisitions, while EBITDA was ₹15.65 crore and PAT ₹8.28 crore; management attributes a dip in consolidated EBITDA margin to sharp raw‑material price inflation and consolidation costs but expects margins to normalize to roughly 25–30%. Management completed the acquisition of a 63.98% stake in Remember India Health Links and has integrated Apiqo Organics and Bizoƫc Lifesciences, expanding installed capacity to a reported 1,400–1,600 MTPA consolidated and positioning Anlon Healthcare to offer backward integrated APIs and finished dosage manufacturing, reducing execution risk and improving regulatory readiness. Management provided explicit growth guidance — targeting ₹350–400 crore revenue for FY27 and aspiring to about ₹700 crore in FY28 — supported by ongoing commissioning of a ~₹130 crore capex to add ~1,200 MTPA standalone capacity and by expected commercialization timelines for CDMO molecules, peptide/biologics initiatives, and formulation approvals. Near-term margin dynamics remain volatile due to geopolitical-driven spikes in solvent and petroleum-derived raw material pricing, with management noting some raw materials rose two to three times; management is implementing price revisions, operational efficiencies and expects EBITDA margins to gradually recover as input prices stabilize and integration benefits materialize.

Over the past 52 weeks, Anlon Healthcare Ltd has traded between a low of ₹10.28 and a high of ₹37.60. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Anlon Healthcare Ltd has a market capitalization of approximately 1,358.02. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Anlon Healthcare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 48.41 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,358.02 Cr, Anlon Healthcare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Anlon Healthcare Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Anlon Healthcare Ltd is 48.41. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Anlon Healthcare set the preferential issue price at ₹17.85 per equity share, stating it matches the independent valuer’s fair value and complies with SEBI ICDR norms.

They approved audited FY26 financial statements, director appointments, an increase in authorised share capital to ₹130 crore, and a preferential issue of up to 8,58,83,617 shares linked to acquisitions.

The 13th AGM is scheduled for September 5, 2026 at 11:00 am (IST) and will be held via video conference.

The AGM is scheduled for September 5, 2026 at 11:00 am and will be conducted via video conference.